

NDA 021572/S-069

SUPPLEMENT APPROVAL

Cubist Pharmaceuticals, LLC, a subsidiary of Merck Sharpe & Dohme, LLC
Attention: Chanel Wong
Senior Specialist, Regulatory Affairs International
351 North Sumneytown Pike
Upper Gwynedd, PA 19454-2505

Dear Chanel Wong:

Please refer to your supplemental new drug application (sNDA) dated and received January 13, 2025, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Cubicin (daptomycin for injection) 500 mg/Vial and Cubicin RF (daptomycin for injection) 500 mg/Vial.

This “Changes Being Effectuated” sNDA provides for revisions to the **HIGHLIGHTS OF PRESCRIBING** section, under the **DOSAGE AND ADMINISTRATION** heading, in the prescribing information (PI). The revisions were made to correct a discrepancy related to the diluent to be used for reconstitution when the products are being administered either by injection over a 2-minute period or by infusion over a 30-minute period. Additionally, this sNDA has been submitted in response to our November 8, 2024, supplement request letter. Minor editorial revisions were also made throughout the PI.

APPROVAL & LABELING

We have completed our review of this application and it is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information) with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling. If the content of labeling in SPL format initially submitted with this CBE-0 labeling supplement is identical to the attached approved labeling, an additional submission of content of labeling in SPL format is not required.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact J. Christopher Davi, MS, Senior Regulatory Project Manager, at (301) 796-0702 or by electronic mail at christopher.davi@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Dmitri Iarikov, MD, PhD
Deputy Director
Division of Anti-Infectives
Office of Infectious Diseases
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information (Cubicin)
 - Prescribing Information (Cubicin RF)

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

DMITRI IARIKOV
05/08/2025 09:54:50 AM